Organon (OGN) Assets Average (2021 - 2026)
Organon (OGN) recorded quarterly Assets Average of $12.9 billion in Q1 2026, down 2.1% quarter-over-quarter from $13.2 billion in Q4 2025, and down 1.5% on a YoY basis from $13.1 billion in Q1 2025.
Organon (OGN) Assets Average (2021 - 2026) Analysis & Trends
Organon's Assets Average history runs 6 years deep, the most recent figure standing at $12.9 billion for Q1 2026.
- In Q1 2026, Assets Average fell 1.5% year-over-year to $12.9 billion; the TTM figure through Mar 2026 stood at $12.9 billion (down 1.5% YoY), while the FY2025 annual figure was $13.0 billion, up 3.22% from the prior year.
- Assets Average was $12.9 billion for Q1 2026 at Organon, down from $13.2 billion in the prior quarter.
- In the past five years, Assets Average ranged from a high of $13.5 billion in Q3 2025 to a low of $10.5 billion in Q3 2022.
- Historically, Assets Average has averaged $11.9 billion across 5 years, with a median of $12.0 billion in 2024.
- The sharpest annual moves came in 2022 and 2024: Assets Average retreated 5.36% in 2022, then advanced 13.26% in 2024.
- A 5-year view of Assets Average shows it stood at $10.7 billion in 2022, then rose by 7.84% to $11.5 billion in 2023, then gained by 12.06% to $12.9 billion in 2024, then rose by 2.19% to $13.2 billion in 2025, then retreated by 2.1% to $12.9 billion in 2026.
- The last three Assets Average figures came in at $12.9 billion (Q1 2026), $13.2 billion (Q4 2025), and $13.5 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,026,132.38 Bn | 93,026,127.42 Bn | 7.76 Bn | 83.03 Bn |
| 2 | Eli Lilly | 1,022.62 Bn | 1,017.34 Bn | 16.22 Bn | 114.53 Bn |
| 3 | Johnson & Johnson | 570.65 Bn | 548.59 Bn | 15.96 Bn | 200.05 Bn |
| 4 | AbbVie | 398.73 Bn | 389.38 Bn | 10.78 Bn | 135.21 Bn |
| 5 | Merck | 295.53 Bn | 289.88 Bn | 12.09 Bn | 132.78 Bn |
| 6 | Amgen | 186.30 Bn | 174.26 Bn | 5.87 Bn | 91.55 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | 57.65 Bn |
| 8 | Pfizer | 146.09 Bn | 133.32 Bn | -1.21 Bn | 208.08 Bn |
| 9 | Bristol Myers Squibb | 114.98 Bn | 104.53 Bn | 8.07 Bn | 88.26 Bn |
| 10 | Organon | 3.49 Bn | 2.37 Bn | 783.00 Mn | 12.93 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.93 Bn |
| Dec 31, 2025 | 13.21 Bn |
| Sep 30, 2025 | 13.53 Bn |
| Jun 30, 2025 | 13.33 Bn |
| Mar 31, 2025 | 13.13 Bn |
| Dec 31, 2024 | 12.93 Bn |
| Sep 30, 2024 | 12.45 Bn |
| Jun 30, 2024 | 12.02 Bn |
| Mar 31, 2024 | 11.97 Bn |
| Dec 31, 2023 | 11.54 Bn |
| Sep 30, 2023 | 11.00 Bn |
| Jun 30, 2023 | 10.87 Bn |
| Mar 31, 2023 | 10.86 Bn |
| Dec 31, 2022 | 10.70 Bn |
| Sep 30, 2022 | 10.53 Bn |
| Jun 30, 2022 | 10.61 Bn |
| Mar 31, 2022 | 10.64 Bn |
| Dec 31, 2021 | 11.01 Bn |
| Sep 30, 2021 | 11.12 Bn |
| Jun 30, 2021 | 10.28 Bn |